Vendor Intelligence Report: Regenerative Research

Published 13 Jun 2026. 23-page investigative report on who is behind Regenerative Research: corporate records, ownership, affiliate networks, and the vendor's lab-testing record. The first 3 pages are free to read on this page.

Researched and published by Finnrick Analytics. Reports draw on corporate records, affiliate-network analysis, and Finnrick's own laboratory testing record; vendors can challenge findings through the formal objections process at finnrick.com/vendor-support/objections.

Executive summary

Across 2 Finnrick lab tests, Regenerative Research is 1 pass / 1 fail, for an overall pass rate of 50%. The independent record is tiny, so this is not a vendor-wide verdict. It is a product-specific signal: Retatrutide is the better-supported current choice, while Tesamorelin is the clear weak spot and should not inherit confidence from the Retatrutide result or from unrelated vendor COAs.

Regenerative Research is also unusually transparent in one area and thin in another. The reviewed public COA library contains 26 batch documents across four laboratories, with two COAs independently verified through lab channels and one Retatrutide batch carrying the most complete QC panel. At the same time, the business record points to a mid-2025, founder-operated Denver storefront rather than an established registered manufacturer.

The supply-chain finding is directional, not cosmetic. The operator publicly rejects a US-made claim and describes Chinese API sourcing, with US fill/finish discussed as a future consideration rather than the current process. That candor is better than vague domestic-origin marketing, but the full report shows why unidentified API manufacturers, overseas lyophilization, a residential business address, and no public Regenerative Research entity still matter for buyers choosing injectable research materials.

Inside the full report:

  • Appendix A — Finnrick Laboratory Data with product-by-methodology charts for Retatrutide and Tesamorelin
  • 26-document COA library review, including Freedom Diagnostics and ILS verification artifacts
  • Identity and launch chronology tying lab submissions, X accounts, WHOIS, and registry searches
  • Supply-chain analysis of Chinese API sourcing, overseas fill/finish, and unresolved manufacturer identity
  • Affiliate and partner review covering SMART10 promotion and the Barrier REGEN15 cross-referral

Risk assessment

  • Tesamorelin quality concern — high: Product-specific: Finnrick's Tesamorelin record is 1 test, 0 pass / 1 fail, current rating 42.46%; buyers should not treat the Retatrutide pass as transferable.
  • Unverified overseas manufacturing and fill/finish chain — high: Catalog-wide: operator says APIs come from Chinese manufacturers and US fill/finish is not yet in place; supplier/fill-site names and audits were not identified.
  • Unregistered-entity accountability risk — medium: Colorado SOS/OpenCorporates returned no Regenerative Research entity; records indicate a Randy Cole-led operation using a Denver residential mailing address.
  • Affiliate-disclosure risk — medium: External X promoter @nick96smart posted SMART10 referral links without clear affiliate/ad disclosure; official and operator accounts also circulate codes.